Fazen Capital

@fazencapital.bsky.social

3 days ago

Bionano Genomics Files DEF 14A on Apr 2 BNGO filed a DEF 14A on Apr 2, 2026; proxy seeks election of 5 directors and approval to add 20m shares — shareholder vote expected June 15, 2026.

Bionano Genomics Files DEF 14A on Apr 2: BNGO filed a DEF 14A on Apr 2, 2026; proxy seeks election of 5 directors and approval to add 20m shares — shareholder vote expected June 15, 2026. 👈 Read full analysis #BionanoGenomics #BNGO #StockMarket #Investing #ShareholderMeeting

StockTitan

@stocktitan.net

4 days ago

In 211 myeloma samples, OGM found abnormalities older tests missed Published in American Journal of Hematology, the 211-sample study says OGM resolved 82% of failed karyotypes and found extra pathogenic events.

#BNGO Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

2 weeks ago

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026 Bionano Genomics (Nasdaq: BNGO) reported Q4 2025 revenue of $8.0M (down 3% YoY) and full‑year 2025 revenue of $28.5M (down 7% YoY). Gross margin improved to 46% FY and installed OGM base reached 387 systems. Company guided 2026 revenue to $30–33M and Q1 2026 to $6.5–6.7M.Operating expenses were cut significantly, cash and equivalents were $29.6M, and CMS increased the 2026 CLFS payment determination by 47% for OGM hematologic code.

#BNGO Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

www.stocktitan.net/news/BNGO/bionano-report...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 weeks ago

Nasdaq Tumbles 2% Amid Rate-Hike Fears: Fear & Greed Index Remains In 'Extreme Fear' Zone - AGI (NYSE:AGBK) The CNN Fear & Greed Index increased due to ongoing conflicts. U.S. stocks closed lower, with Nasdaq down 2%, while energy and financial sectors gained.

Nasdaq Tumbles 2% Amid Rate-Hike Fears: Fear & Greed Index Remains In 'Extreme Fear' Zone The CNN Fear & Greed Index increased due to ongoing conflicts. U.S. stocks closed lower, wi...

#AGBK #BNGO #CMCL #CNN #Business #Fear #& #Greed #Index #Earnings #Equities

Origin | Interest | Match

StockTitan

@stocktitan.net

2 weeks ago

Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Bionano (NASDAQ: BNGO) reported that 12 optical genome mapping (OGM) studies were presented at the 2026 ACMG Annual Meeting (March 14–18), a two-fold increase versus 2025. Presentations included four oral talks and eight posters across cancer genomics and constitutional genetic disorders.The presentations highlighted OGM's ability to detect structural variants missed by other methods; a Greenwood Genetic Center workshop and a Baylor Genetics commercial OGM service release were also noted.

#BNGO Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

1 month ago

Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and molecular pathology laboratories in the United

#BNGO Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale

www.stocktitan.net/news/BNGO/bionano-sympos...

StockTitan

@stocktitan.net

1 month ago

10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders Bionano (Nasdaq: BNGO) highlighted Day 3 of Symposium 2026 on Feb 26, 2026, focused on optical genome mapping (OGM) in constitutional genetic disorders. Attendance exceeded 1,200 participants from >73 countries and the online poster hall featured 50 posters. Presentations reported study detection rates, case examples, and VIA software use for SV interpretation.

#BNGO 10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders

www.stocktitan.net/news/BNGO/10-presentatio...

StockTitan

@stocktitan.net

3 months ago

Bionano Genomics (NASDAQ: BNGO) details 13 optical genome mapping studies at AMP 2025 Bionano recaps 13 studies from AMP 2025 showing how optical genome mapping aids SV detection, integrates with NGS workflows, and supports oncology and inherited disease research.

#BNGO Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025

www.stocktitan.net/news/BNGO/bionano-recaps...

StockTitan

@stocktitan.net

4 months ago

#BNGO Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies

www.stocktitan.net/news/BNGO/final-2026-cli...

StockTitan

@stocktitan.net

5 months ago

Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia Bionano (Nasdaq: BNGO) announced a peer-reviewed MD Anderson study published in Cancers showing optical genome mapping (OGM) can overcome key limitations of targeted RNA-seq for detecting gene rearrangements in acute leukemia.In a cohort of 467 subjects, 234 gene rearrangements/fusions were detected across 206 subjects (43.6%). OGM and RNA-seq both detected 175 events (74.7% of positives); OGM uniquely found 37 events (15.8%) and RNA-seq uniquely found 22 (9.4%). Tier 1 aberrations appeared in 147 subjects (31.5%). RNA-seq detected only 20.6% of enhancer-hijacking events found by OGM. The study concludes OGM plus RNA-seq yields the most comprehensive genomic profiling in acute leukemia.

#BNGO Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia

www.stocktitan.net/news/BNGO/bionano-announ...

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks in new downtrend according to ave directional index, Mon Nov 3rd - #XBIT #UDMY #BNGO #FSUN #GBIO #HTOO #KPET #LINC #OSUR #PNBK #RBBN #SHFS #VRE #SKLZ #PBI #OMI #MLR #KW #HNI #GBX #EIG #DFIN #CION #AHH - More: crystalequityresearch.com/trade-alerts... - #smallcap

StockTitan

@stocktitan.net

6 months ago

$30M Total Potential: Bionano Genomics Launches Strategic Public Offering with 5-Year Warrants Biotech firm prices 5M shares at $2.00 with Series E and F warrants. Additional $20M possible from warrant exercise. Closing expected Sept 17. H.C. Wainwright acts as placement agent.

#BNGO Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

www.stocktitan.net/news/BNGO/bionano-genomi...

StockTitan

@stocktitan.net

7 months ago

Bionano Genomics Shifts Strategy: Cost Cuts and Higher Margins Signal Turnaround Progress Bionano achieves 52% gross margin through strategic pivot to routine users, cuts operating costs by 42%. Company maintains $26-30M revenue outlook for 2025. See full results.

#BNGO Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

www.stocktitan.net/news/BNGO/bionano-report...

StockTitan

@stocktitan.net

7 months ago

Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL Bionano Genomics (NASDAQ:BNGO) announced a significant peer-reviewed publication demonstrating the effectiveness of their optical genome mapping (OGM) technology in detecting oncogenic structural variants in infant and toddler T-cell acute lymphoblastic leukemia (T-ALL).The study, conducted across multiple French pediatric centers, analyzed 27 T-ALL cases in children under 3 years. Key findings include: 33% of cases carried previously uncharacterized NKX2 gene rearrangements, distinct genomic profiles compared to older children, and a 75.4% five-year overall survival rate. The research demonstrated OGM's ability to identify prognostic subgroups and detect complex genetic rearrangements in a single workflow, potentially improving disease classification and management.

#BNGO Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

8 months ago

Bionano's New AI Software Doubles Cancer Sample Analysis Speed, Transforms Genomic Testing Workflow Advanced AI technology enhances genomic variant detection with 18% larger database and doubled cancer sample processing speed. See how this transforms genetic testing.

#BNGO Bionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More Accurate

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

8 months ago

European Genetics Conference Showcases Record-Breaking 16 Studies Validating Optical Genome Mapping Technology New research from 7 countries reveals expanding applications of OGM in cancer and genetic testing. Growth in scientific presentations signals rising clinical adoption. Learn more.

#BNGO Bionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium

www.stocktitan.net/news/BNGO/bionano-recaps...

StockTitan

@stocktitan.net

9 months ago

Breakthrough Genetic Research: 21 Studies from 12 Countries Showcase Bionano's Technology at European Conference New research from 12 countries reveals breakthrough applications in genetic disease detection. Clinical studies demonstrate superior variant detection - see key findings.

#BNGO Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy

www.stocktitan.net/news/BNGO/bionano-recaps...

StockTitan

@stocktitan.net

10 months ago

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress Bionano Genomics (NASDAQ: BNGO) reported Q1 2025 financial results, showing mixed performance. Total revenue decreased 26% to $6.5 million compared to Q1 2024's $8.8 million. However, the company improved its GAAP gross margin to 46% from 32% year-over-year. The company sold 6,994 nanochannel array flowcells, down 15% YoY, but noted 82% were sold to routine users. The installed base grew to 379 OGM systems, a 9% increase from Q1 2024. Operating expenses decreased significantly by 66% to $11.4 million. The company raised additional capital through a $10 million Registered Direct Offering and $3.2 million in ATM sales. Bionano updated its 2025 outlook, projecting full-year revenue of $26.0-30.0 million and expects to install 15-20 new OGM systems. Cash position stands at $29.2 million, with runway extended into Q1 2026.

#BNGO Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

www.stocktitan.net/news/BNGO/bionano-report...

Market Wire News

@marketwirenews.com

11 months ago

Just In: ( NASDAQ: #BNGO ) BioNano Genomics Inc. (NASDAQ: BNGO) Sees Notable Increase in Thursday Morning Market Activity

StockTitan

@stocktitan.net

11 months ago

Breakthrough: French Study Reveals Game-Changing Multiple Myeloma Detection Method Revolutionary study validates new multiple myeloma analysis method requiring 50% fewer cells while detecting 22 additional genetic variants. Full clinical implications inside.

#BNGO Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

1 year ago

Bionano Earnings: Mixed Q4 Results Show 42% Margins as Company Slashes $100M in Costs Q4 gross margins surge to 42% amid cost-cutting success. Installed base grows 14% while flowcell sales rise 15%. See full analysis of BNGO's transformation strategy.

#BNGO Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025

www.stocktitan.net/news/BNGO/bionano-report...

StockTitan

@stocktitan.net

1 year ago

Major Discovery: New Genes Linked to Birth Defects Found Using Advanced DNA Mapping Groundbreaking research identifies 4 novel genes linked to neural tube defects, advancing understanding of birth defects affecting 300,000 babies annually. Full analysis inside.

#BNGO Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect

www.stocktitan.net/news/BNGO/study-using-og...

StockTitan

@stocktitan.net

1 year ago

Major Cancer Breakthrough: New Technology Identifies Hidden AML Risk Factor Linked to 66% Lower Survival Rate MD Anderson study validates Bionano's OGM technology in detecting crucial AML prognostic marker. Research reveals 16% of cases show chromoanagenesis, linked to dramatically reduced survival.

#BNGO Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML

www.stocktitan.net/news/BNGO/bionano-announ...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with bullish crossover of Moving Average Convergence Divergence signal, Tue Feb 11th - #UNIT #TLSA #APCX #BNGO #CRCT #FORR #HPK #KERN #MSBI #NEXN #SHIP #ONDS #THR #MKFG #LZM #KNOP #GES #CATO #BKD #ADNT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #BNGO ) How the (BNGO) price action is used to our Advantage

StockTitan

@stocktitan.net

1 year ago

Bionano Announces Effective Date of Reverse Stock Split Bionano Genomics (BNGO) has announced a 1-for-60 reverse stock split of its common stock, effective at 5 p.m. ET on January 24, 2025. Trading on a split-adjusted basis will begin on January 27, 2025. The split was approved by stockholders at a special meeting on January 15, 2025, where the Board was authorized to implement a ratio between 1-for-25 and 1-for-75.The reverse split will automatically convert every 60 existing shares into one new share. The stock will continue trading under the symbol 'BNGO' on Nasdaq Capital Market but with a new CUSIP number (09075F404). The split proportionally affects all outstanding convertible debentures, stock options, restricted stock units, and warrants, adjusting their conversion and exercise prices accordingly. No fractional shares will be issued; instead, affected stockholders will receive cash payments.

#BNGO Bionano Announces Effective Date of Reverse Stock Split

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

1 year ago

Bionano's Genome Mapping Tech Enables Breakthrough in IVF Success After Recurrent Pregnancy Loss Bionano's OGM technology helped identify complex chromosomal issues missed by traditional methods, leading to successful pregnancy in breakthrough fertility case study.

#BNGO Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

www.stocktitan.net/news/BNGO/bionano-announ...

StockTitan

@stocktitan.net

1 year ago

Bionano Q4 Revenue Dips 25% YoY But Shows Strong Sequential Growth, OGM System Base Expands 14% Bionano reports mixed Q4 results with sequential revenue growth of 30-33% despite YoY decline. OGM installed base reaches 371 systems as Stratys launch drives expansion.

#BNGO Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results

www.stocktitan.net/news/BNGO/bionano-report...

StockTitan

@stocktitan.net

1 year ago

Johns Hopkins Study: Bionano's Genome Mapping Detects Hidden Leukemia Variants Missed by Standard Tests New research shows Bionano's optical genome mapping successfully identified important leukemia mutations missed by conventional methods, potentially improving cancer treatment decisions.

#BNGO Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

www.stocktitan.net/news/BNGO/bionano-announ...

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #BNGO ) Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

#StockMarket #News